Literature DB >> 26602283

Neurobiological changes by cytotoxic agents in mice.

R Seigers1, M Loos2, O Van Tellingen3, W Boogerd4, A B Smit5, S B Schagen6.   

Abstract

Cognitive deficit is a frequently reported side-effect of adjuvant chemotherapy. A large number of animal studies has been performed to examine the neurobiological mechanisms underlying this phenomenon, however, definite conclusions from these studies are restricted due to differences in experimental set-up. We systematically investigated the effects of 6 cytotoxic agents on various neurobiological parameters. C57Bl/6J mice were treated with cyclophosphamide, docetaxel, doxorubicin, 5-fluorouracil, methotrexate, or topotecan. The animals were sacrificed 3 or 15 weeks after treatment and the effect on neurogenesis, blood vessel density, and neuroinflammation was analyzed using immunohistochemistry. None of the cytostatic agents tested affected neurogenesis (cell survival or cell proliferation). Blood vessel density was increased in the hippocampus and prefrontal cortex 3 weeks after treatment with docetaxel and doxorubicin compared with control animals. A decrease in the number of microglial cells was observed in the prefrontal cortex after treatment with cyclophosphamide, docetaxel, 5-FU, and topotecan compared with control mice. The observed decrease in microglia cells is indicative of inflammation that occurred after treatment. Overall, the magnitude of the effects was relatively modest. Therefore, we conducted a similar study with topotecan in Abcg2;Abcb1a/b knock out and wildtype FVB mice. Animals were sacrificed 3 weeks after treatment and no notable effect was seen in hippocampal cell differentiation (DCX), microglia activation, or blood vessel density. Perhaps the FVB strain is more resistant to the neurotoxic effects of topotecan which makes this not the correct model to study the mechanism of chemotherapy-induced cognitive impairment.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood vessels; Chemotherapy; Immunohistochemistry; Inflammation; Mouse; Neurogenesis

Mesh:

Substances:

Year:  2015        PMID: 26602283     DOI: 10.1016/j.bbr.2015.10.057

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  17 in total

Review 1.  Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.

Authors:  M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

Review 2.  Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities.

Authors:  Kelley R Jordan; Brett R Loman; Michael T Bailey; Leah M Pyter
Journal:  Cancer       Date:  2018-07-05       Impact factor: 6.860

3.  Long-term clinically relevant rodent model of methotrexate-induced cognitive impairment.

Authors:  Connor Berlin; Katharine Lange; H Carl Lekaye; Kelsey Hopland; Samantha Phillips; Jinghua Piao; Viviane Tabar
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

4.  Altered intrinsic brain activity after chemotherapy in patients with gastric cancer: A preliminary study.

Authors:  Hyun Gi Kim; Na-Young Shin; Yunjin Bak; Kyung Ran Kim; Young-Chul Jung; Kyunghwa Han; Seung-Koo Lee; Soo Mee Lim
Journal:  Eur Radiol       Date:  2016-11-23       Impact factor: 5.315

5.  Effects of Cyclophosphamide and/or Doxorubicin in a Murine Model of Postchemotherapy Cognitive Impairment.

Authors:  Timothy J Flanigan; Julie E Anderson; Ikram Elayan; Antiño R Allen; Sherry A Ferguson
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

6.  Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.

Authors:  Lauren E Himmel; Maryam B Lustberg; A Courtney DeVries; Ming Poi; Ching-Shih Chen; Samuel K Kulp
Journal:  Exp Toxicol Pathol       Date:  2016-08-21

7.  Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients.

Authors:  Jeroen Blommaert; Gwen Schroyen; Mathieu Vandenbulcke; Ahmed Radwan; Ann Smeets; Ron Peeters; Charlotte Sleurs; Patrick Neven; Hans Wildiers; Frédéric Amant; Stefan Sunaert; Sabine Deprez
Journal:  Hum Brain Mapp       Date:  2019-08-21       Impact factor: 5.038

Review 8.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

Review 9.  Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2021-11-02       Impact factor: 5.153

10.  Development of a Human APOE Knock-in Mouse Model for Study of Cognitive Function After Cancer Chemotherapy.

Authors:  Andrew P Speidell; Tamar Demby; Yichien Lee; Olga Rodriguez; Christopher Albanese; Jeanne Mandelblatt; G William Rebeck
Journal:  Neurotox Res       Date:  2018-10-04       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.